Progressive Multifocal Leukoencephalopathy as a Complication of Hepatitis C Virus Treatment in an HIV-Negative Patient
Authors:
Open Access
- 1 August 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (3) , 417-419
Abstract
SIR—It is estimated that >170 million individuals are infected with hepatitis C virus (HCV) worldwide. To date, combination therapy with pegylated IFN-α 2a or 2b and ribavirin has been shown to be the most effective treatment and can eradicate HCV in >50% of affected individuals [1]. However, serious side effects are associated with this treatment, including leukopenia and a potential risk of opportunistic infections [2, 3]. We describe a patient who developed progressive multifocal leukoencephalopathy (PML) while receiving pegylated IFN-α and ribavirin therapy for HCV infection.Keywords
This publication has 8 references indexed in Scilit:
- The Human Polyomavirus, JCV, Uses Serotonin Receptors to Infect CellsScience, 2004
- New insights into progressive multifocal leukoencephalopathyCurrent Opinion in Neurology, 2004
- Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patientsAIDS, 2004
- Viral hepatitis CThe Lancet, 2003
- Hematologic Disorders Associated with Hepatitis C Virus Infection and Their ManagementClinical Infectious Diseases, 2003
- Side effects of therapy of hepatitis C and their managementHepatology, 2002
- Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinosideJournal of NeuroVirology, 2001
- Leucoencefalopatía multifocal progresiva en pacientes ancianos inmunocompetentes. A propósito de dos casosRevista De Neurologia, 1999